PTGS2 and neoplasm: Immunohistochemistry revealed that p65 localisation was predominantly cytoplasmic in tumour cells from the Mel and Mel + TMZ groups, aligning with the in vitro findings that Mel enhances TMZ efficacy by inhibiting the NF‐κB/COX‐2 signalling pathway.